Relación neutrófilos-linfocitos como predictor de riesgo de recurrencia de cáncer de tiroides

Introduction. The neutrophil-to-lymphocyte ratio (NLR) is an inflammatory biomarker associated with poor prognosis and recurrence in differentiated thyroid cancer (DTC). Its usefulness as a complementary tool to the American Thyroid Association (ATA) risk stratification still requires clinical valid...

Descripción completa

Detalles Bibliográficos
Autores: Paz-Ibarra, José Luis, Herrera Silvestre, Hilder Daladier, Yovera-Aldana, Marlon Augusto, Concepción-Zavaleta, Marcio José
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:Perú
Institución:Universidad Nacional Mayor de San Marcos
Repositorio:Revistas - Universidad Nacional Mayor de San Marcos
Idioma:español
OAI Identifier:oai:revistasinvestigacion.unmsm.edu.pe:article/31278
Acceso en línea:https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/31278
Access Level:acceso abierto
Palabra clave:Neutrófilos
Linfocitos
Inflamación
Neoplasias de la Tiroides
Recurrencia
Neutrophil
Lymphocyte
Inflammation
Thyroid Cancer
Recurrence
Descripción
Sumario:Introduction. The neutrophil-to-lymphocyte ratio (NLR) is an inflammatory biomarker associated with poor prognosis and recurrence in differentiated thyroid cancer (DTC). Its usefulness as a complementary tool to the American Thyroid Association (ATA) risk stratification still requires clinical validation. Objective. To assess the discriminatory ability of the neutrophil-to-lymphocyte ratio as a predictor of thyroid cancer recurrence risk. Methods. A cross-sectional, analytical, observational study conducted at the Edgardo Rebagliati Martins National Hospital EsSalud between June 2023 and June 2024. Patients diagnosed with DTC who had undergone total thyroidectomy and had available preoperative blood counts were included; those with inflammatory or infectious processes, additional neoplasia, or use of immunosuppressants were excluded. According to ATA 2015, patients were classified as low, intermediate, and high risk of recurrence. Discriminatory capacity and optimal cutoff points were evaluated using ROC curves. Results. 104 patients were analyzed, with a mean age of 51,9 ± 13,5 years, with a female predominance (87,5%). The 41,4% were classified as having low risk of recurrence, 53,9% as intermediate, and 4,8% as high. The AUC for differentiating high vs. low-intermediate risk was 0,69 (95% CI: 0,43–0,95), and for intermediate-high vs. low risk it was 0,58 (95% CI: 0,47–0,69). Conclusion. The NLR did not show discriminatory ability to differentiate the levels of recurrence risk in thyroid cancer according to the ATA classification.